Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /  Forum  /  Acacia Pharma  /  Acacia Pharma 2020

Acacia Pharma« Terug naar discussie overzicht

Acacia Pharma 2020

Volgen
7.932 Posts
Pagina: «« 1 ... 194 195 196 197 198 ... 397 »» | Laatste | Omlaag ↓
  1. Rode Duivel 13 augustus 2020 08:27
    quote:

    BrechtDomen schreef op 12 augustus 2020 18:41:

    [...]

    100% mee eens. En dat is de taak van Acacia. Misschien moeten ze eens wat investeren in een goede communicatiedienst ?
    Acacia is een klein bedrijf met beperkte middelen. Het is vast mogelijk dat de PR-rol vervuld wordt door een persoon met meerdere verantwoordelijkheden. Het laatste waar zij van wakker gaan liggen zijn ongeduldige korte-termijn-beleggers.
  11. Sirlander 13 augustus 2020 14:43
    quote:

    Riske2 schreef op 13 augustus 2020 14:34:

    Sirlander, dit is goed nieuws.
    klopt niet hoor... was een test ;).

    heb wel ondertussen eens gekeken hoelang een beslissing van de DEA duurt en dit is het antwoord:
    52 days
    Presently, the average time it takes for DEA and the FDA to review/approve an application is 52 days.

    We zitten nu aan 41 dagen.
  15. Rode Duivel 13 augustus 2020 15:08
    Acacia Pharma Group plc

    Proposed Capital Raising by way of a Placing of New Ordinary Shares

    Cambridge, UK and Indianapolis, US – 13 August 2020: Acacia Pharma Group plc ("Acacia Pharma" or the "Company") (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy, intends to issue new ordinary shares of a nominal value of £0.02 (the "New Ordinary Shares") raising gross proceeds of approximately EUR 25m ($30m), by means of an accelerated bookbuild offering (the "Placing").

    The price at which the New Ordinary Shares will be issued (the "Placing Price") and the total number of New Ordinary Shares to be issued in the Placing will be determined by way of an accelerated bookbuild process (the "Bookbuild"). The Company believes that using the flexibility provided by a non-pre-emptive placing is the most appropriate structure for the Company at this time, allowing it to raise capital in a timely and cost-effective manner and to diversify the shareholder base.

    Jefferies International Limited ("Jefferies") and Guggenheim Securities, LLC ("Guggenheim Securities") are acting as Joint Global Coordinators and Joint Bookrunners and Bank Degroof Petercam SA/NV ("Degroof Petercam") is acting as Joint Bookrunner and Listing Agent (Jefferies, Guggenheim Securities and Degroof Petercam together, the “Joint Bookrunners” or the "Banks") in connection with the Placing.

    The Bookbuild will start immediately following this announcement. Pricing and allocation of the New Ordinary Shares in the Placing is expected to take place before beginning of trading on Euronext Brussels at 09:00 CEST on 14 August 2020. The exact timing of closing of the Bookbuild, pricing and allocation is at the discretion of the Company and the Joint Global Coordinators and Joint Bookrunners. The Company will announce the outcome of the Placing after closing of the Bookbuild in a subsequent announcement.

    The Company has requested the Belgian Financial Services and Markets Authority ("Belgian FSMA") to suspend trading in Acacia Pharma’s shares on Euronext Brussels during the Bookbuild. Trading in the shares is expected to resume following the publication of the results of the Placing.

    The Company has separately announced today its interim results for the six months ended 30 June 2020 (the “Interim Results Announcement”). This announcement should be read in conjunction with the Interim Results Announcement.

    The net proceeds of the Placing are intended to be used for:
    (i) the recruitment of an initial sales force of approximately 30, with an additional ten support staff;
    (ii) payment of marketing costs relating to BARHEMSYS® and BYFAVO™ including brand development and engagement with key opinion leaders, healthcare professionals and medical conference and speaker programmes;
    (iii) the implementation of post-approval research and development commitments including paediatric studies for BARHEMSYS® and BYFAVO™ and a renal study for BARHEMSYS®;
    (iv) satisfaction of interest and capital payments under existing loan agreements; and
    (v) general corporate purposes relating to ongoing commercial activities as well as supplementing existing stock of both BARHEMSYS® and BYFAVO™.

    In connection with the Placing, the Company has agreed, pursuant to a lock-up undertaking, not to issue additional shares for a period of 90 days following settlement of the Placing. In addition, in connection with the Placing, senior managers and directors of the Company as well as Cosmo Technologies Limited, a substantial shareholder in the Company, have agreed not to sell any shares in Acacia Pharma for a period of 90 days following the settlement of the Placing, subject to customary exceptions.

    Your attention is drawn to the detailed terms and conditions of the Placing described in Appendix I to this announcement (which form part of this announcement). The attention of investors is drawn in particular to the "Conditions of the Placing and Termination of the Placing Agreement" section of Appendix I (including the condition that no Material Adverse Change can have occurred immediately prior to the Closing Date and, in respect of termination of the Placing Agreement, the various applicable force majeure events set out therein).

    Capitalised terms used but not otherwise defined in the text of this announcement are defined in Appendix II of this announcement.
7.932 Posts
Pagina: «« 1 ... 194 195 196 197 198 ... 397 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
Alfen N.V. 13,190 +0,51 +4,02%
BESI 113,800 +3,60 +3,27%
ASML 792,000 +21,30 +2,76%
INPOST 17,780 +0,44 +2,54%
THEON INTERNAT 10,200 +0,25 +2,51%
TomTom 5,340 +0,13 +2,50%
ASMI 589,000 +13,80 +2,40%
Pharming 0,782 +0,02 +2,09%
ADYEN NV 1.387,000 +25,40 +1,87%
AZERION 1,450 +0,02 +1,68%
TKH 38,160 +0,56 +1,49%
Wolters Kluwer 157,000 +2,30 +1,49%
CM.COM 6,900 +0,09 +1,32%
EXOR NV 98,000 +1,15 +1,19%
NX FILTRATION 4,650 +0,05 +1,09%
AALBERTS NV 34,720 +0,36 +1,05%
KPN 3,728 +0,04 +1,03%
PROSUS 40,175 +0,37 +0,93%
ASR Nederland 44,400 +0,38 +0,86%
EBUSCO HOLDING 0,703 +0,01 +0,79%
RELX 43,240 +0,32 +0,75%
AEX 922,63 +6,67 +0,73%
Brunel 8,820 +0,06 +0,68%
Accsys 0,618 +0,00 +0,65%
Arcadis 64,550 +0,40 +0,62%
NN Group 45,460 +0,27 +0,60%
RANDSTAD NV 43,970 +0,23 +0,53%
UNILEVER PLC 57,660 +0,30 +0,52%
Fugro 21,600 +0,10 +0,47%
ForFarmers 3,315 +0,02 +0,45%
CTP 16,800 +0,06 +0,36%
SIGNIFY NV 22,400 +0,08 +0,36%
ACOMO 17,500 +0,06 +0,34%
AMX 901,91 +2,80 +0,31%
DSM FIRMENICH AG 115,400 +0,35 +0,30%
Galapagos 26,880 +0,08 +0,30%
Vopak 42,820 +0,12 +0,28%
JUST EAT TAKEAWAY 12,725 +0,03 +0,24%
Kendrion 11,260 +0,02 +0,18%
Sif Holding 14,500 +0,02 +0,14%
SHELL PLC 31,280 +0,02 +0,05%
Aegon 5,716 +0,00 +0,04%
ING 15,954 +0,00 +0,03%
B&S Group SA 4,770 0,00 0,00%
Eurocommercial Properties 24,650 0,00 0,00%
Philips Koninklijke 29,380 0,00 0,00%
WDP 23,440 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
Ahold Delhaize 30,070 -1,09 -3,50%
HEIJMANS KON 26,850 -0,80 -2,89%
Avantium 2,555 -0,07 -2,85%
PostNL 1,153 -0,02 -1,62%
Sligro 12,240 -0,20 -1,61%
Vastned 24,600 -0,35 -1,40%
FASTNED 21,300 -0,30 -1,39%
Air France-KLM 8,366 -0,11 -1,27%
AMG Critical Materials N.V. 16,630 -0,16 -0,95%
Fagron 18,700 -0,16 -0,85%
Aperam 25,800 -0,20 -0,77%
ArcelorMittal 22,520 -0,16 -0,71%
OCI 26,900 -0,18 -0,66%
Flow Traders 21,140 -0,12 -0,56%
Wereldhave 14,860 -0,08 -0,54%
NSI 20,550 -0,10 -0,48%
JDE PEET'S 18,350 -0,08 -0,43%
Akzo Nobel 63,400 -0,26 -0,41%
Nedap N.V. 57,000 -0,20 -0,35%
ASCX 1.268,15 -3,34 -0,26%
UMG 23,630 -0,06 -0,25%
SBM Offshore 17,210 -0,03 -0,17%
Basic-Fit 24,320 -0,04 -0,16%
IMCD 152,650 -0,25 -0,16%
BAM 4,544 -0,01 -0,13%
Heineken 77,100 -0,10 -0,13%
RENEWI 7,710 -0,01 -0,13%
Van Lanschot Kempen NV 44,600 -0,05 -0,11%
ALLFUNDS GROUP 5,200 0,00 -0,10%
Corbion 25,000 -0,02 -0,08%
ABN AMRO BANK N.V. 15,830 -0,01 -0,03%
vlag naam koers verschil relatief verschil
AEX 922,63 +6,67 +0,73%
AEX GR 3.606,07 +26,07 +0,73%
Germany40^ 19.535,80 +161,97 +0,84%
FTSE 100 8.292,66 +39,01 +0,47%
EURO50 5.049,69 +45,52 +0,91%
US30^ 43.095,20 +223,60 +0,52%
Nasd100^ 20.443,30 +168,90 +0,83%
US500^ 5.863,31 +46,21 +0,79%
Japan225^ 40.073,80 +236,40 +0,59%
VD-NEW 16,04 -0,65 -3,89%
#/^ Index indications calculated real time, zie disclaimer